Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition

SIMPLE SUMMARY: Immune checkpoint blockade has dramatically improved the outcomes of patients with melanoma. Available long-term updates of clinical studies show a sustained clinical benefit for patients treated with PD-1 inhibitors such as nivolumab or pembrolizumab or for those treated with a comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassel, Jessica C., Zimmer, Lisa, Sickmann, Thomas, Eigentler, Thomas K., Meier, Friedegund, Mohr, Peter, Pukrop, Tobias, Roesch, Alexander, Vordermark, Dirk, Wendl, Christina, Gutzmer, Ralf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341224/
https://www.ncbi.nlm.nih.gov/pubmed/37444558
http://dx.doi.org/10.3390/cancers15133448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341224/
https://www.ncbi.nlm.nih.gov/pubmed/37444558
http://dx.doi.org/10.3390/cancers15133448

Ejemplares similares